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Aging and efficacy of disease-modifying
therapies in multiple sclerosis: a metaanalysis of clinical trials
Yinan Zhang, Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, Gary Cutter,
William Culpepper II, Mitchell Wallin, Peter Kosa, Bibiana Bielekova,
Fred Lublin and Olaf Stuve

Abstract
Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for the
treatment of disease activity and are effective in reducing relapses and new magnetic resonance
imaging (MRI) lesions. However, disease activity generally subsides with time, and age-dependent
changes in DMT efficacy are not well-established. We aimed to investigate whether age impacts
the efficacy of DMTs in treating disease activity in patients with relapsing–remitting MS (RRMS).
Methods: DMT efficacy related to age was assessed through a meta-analysis of clinical
trials that evaluated the efficacy of DMTs in RRMS patients as measured by reductions in the
annualized relapse rate (ARR), new T2 lesions, and gadolinium-enhanced lesions on MRI.
Using the mean baseline patient age from each trial, a weighted linear regression was fitted to
determine whether age was associated with treatment efficacy on a group level.
Results: Group-level data from a total of 28,082 patients from 26 trials of 14 different DMTs
were included in the meta-analysis. There were no statistically significant associations
between age and reductions in ARR, new T2 lesions, and gadolinium-enhanced lesions of the
treatment group compared with placebo.
Conclusion: DMTs for RRMS show efficacy in treating disease activity independent of age as
demonstrated by group-level data from DMT clinical trials. Nevertheless, clinical trials select
for patients with baseline disease activity regardless of age, thereby not representing realworld patients with RRMS, where disease activity declines with age.
Keywords: multiple sclerosis, clinical trials, aging, disease-modifying therapies
Received: 9 July 2020; revised manuscript accepted: 14 September 2020.

Introduction
Multiple sclerosis (MS) is a chronic immunemediated inflammatory disorder of the central
nervous system characterized by demyelination
and neurodegeneration.1 Two broad categories
divide the disease into relapsing–remitting (RRMS)
and progressive (PMS) phenotypes. RRMS is
characterized by attacks of new or worsening
neurological deficits with or without return to

baseline while PMS commonly presents with progressive worsening of neurologic disability.2 While
there is currently no cure for the disease, over a
dozen disease-modifying therapies (DMTs) are
approved by regulatory agencies for the treatment
of disease activity primarily based on reducing
relapses and formation of new magnetic r esonance
imaging (MRI) lesions.

The majority of DMTs treat disease activity by
depleting inflammatory cells, preventing their migration into the central nervous system and mitigating
formation of new focal white matter lesions. This
efficacy for treating disease activity has prompted trials of many of the same DMTs in people with PMS,
but most failed to halt disease progression, likely due
to the late intrathecal inflammatory process occurring in the setting of an intact blood–brain barrier
that is more difficult to target.3–6
Age appears to be a strong predictor of MS disease activity. With increasing age, relapse frequency and new inflammatory MRI lesions
decline;7–9 however, there is scarce evidence on
age-dependent changes in DMT efficacy in treating disease activity. The goal of this study was to
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perform a meta-analysis of all blinded, randomized clinical trials of DMTs for RRMS to
examine whether reductions in disease activity
on a group level as measured by annualized
relapse rate (ARR), new T2 lesions, and gadolinium-enhanced lesions are dependent on age. We
hypothesized that age will negatively correlate
with reductions in ARR, new T2 lesions, and
gadolinium-enhanced lesions in people with
RRMS. Establishing an association between
aging and DMT efficacy will help predict treatment response in patients and inform treatment
decisions given the inherent risks of adverse
effects, particularly in elderly patients with MS,
and the high cost of DMTs.
Methods
Search strategy and selection criteria
We searched PubMed from the database inception to
May 2020 for clinical trials of DMTs for the treatment of RRMS. The “clinical trial” filter in PubMed
was applied and key words for screening included
“multiple sclerosis” in conjunction with either “interferon” (n = 908), “glatiramer acetate” (n = 211),
“dimethyl fumarate” (n = 35), “fingolimod” (n = 89),
“siponimod” (n = 5), “ozanimod” (n = 6), “teriflunomide” (n = 25), “cladribine” (n = 37), “alemtuzumab”
(n = 34),
“mitoxantrone”
(n = 54),
“natalizumab” (n = 107), “rituximab” (n = 22),
“ocrelizumab” (n = 10), “daclizumab” (n = 36), and
“laquinimod” (n = 13). Eligibility criteria included
blinded randomized phase III clinical trials in adult
patients with RRMS, intervention with any of the
aforementioned pharmacological agents for at least
1 year, the inclusion of a placebo control arm or interferon beta as the active comparator arm, availability
of baseline patient characteristics including mean
age, and outcome measurements including ARR,
new T2 lesions, and/or gadolinium-enhanced lesions.
Studies were excluded if more than 10% of the trial
population consisted of patients with PMS. Full texts
of all articles were obtained based on the assessments
of titles and abstracts, and additional information
from supplementary data was gathered when applicable. The screening process is depicted in the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses flow diagram (Figure 1).10
Data analysis
Extracted data included clinical trial characteristics
(name of trial, year of publication, interventions,
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study duration, sample size), mean age of trial subjects, and outcome measures (ARR, new T2
lesions, and gadolinium-enhanced lesions). When
mean values were not available, the reported
median values were used. The analytic methods
were adopted from a meta-analysis by Weideman
et al.11 Data analysis was conducted in statistical
software R v.3.3.1 (RStudio v.1.0).12,13
Calculating ARR, new T2 lesions, and
gadolinium-enhanced lesions reduction
Drug efficacy was measured by percent reduction
in ARR, new T2 lesions, and gadoliniumenhanced lesions of the drug group against the
placebo group. Using ARR as the example, this
was calculated as


ARR drug
%ARR reduction = 1 −
 ARR placebo



 ⋅100%



where ARRdrug represents the ARR of the drug
group and ARRplacebo represents the ARR of the
placebo group at the end of the trial. The ratio
of ARRdrug to ARRplacebo can be viewed as the
number of relapses occurring on treatment to
the number of relapses occurring while on placebo. Thus, ARR reduction is roughly equivalent to the relative risk reduction in relapse
occurrences.
Assigning trial weight
A weighted regression was used to account for the
varying sample size and duration of clinical trials.
Using methods from previous meta-analyses,14,15
the estimated weight of each trial was calculated
using the following formula:
Weight = n D
where n is the trial sample size and D is the trial
duration in years. Therefore, trials enrolling
more subjects and lasting longer will carry a
larger weight. For trials with two treatment arms
and one control arm, each pair of treatment versus control arms was considered an independent
trial. To avoid double counting patients and
falsely inflating the trial weight, the placebo
group size used in calculating each trial sample
size was divided by the number of treatment
arms.
journals.sagepub.com/home/tan
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram illustrating
search strategy and study inclusion in the meta-analysis.

Estimating efficacy against placebo in active
comparator trials
For trials not using placebo, various interferon
beta formulations were used as the active comparator. To estimate drug efficacy against placebo in
active comparator trials, we factored in an estimated additional efficacy of interferon beta preparations against placebo on top of the known efficacy
of the drug against the interferon beta control.
Using ARR as the example, the ARR reduction of
the drug versus placebo in active comparator studies using interferon beta can be thought of as
ARR reduction Drug versus placebo

ARR drug ARR IFN −β
= 1 −
⋅
 ARR IFN −β ARR placebo


journals.sagepub.com/home/tan


 ⋅100%



This represents the additional ARR reduction that a
drug that was compared with interferon beta (IFNβ) would have against placebo by factoring in the
ARR reduction that interferon beta preparations as
a group have against placebo. By rearranging the
equation for ARR reduction, it holds true that

ARR reduction Drug versus placebo =
  ARR reduction Drug versus IFN −β  
1 − 1 −
 ⋅ 
100
 
 

 ⋅100%
 1 − ARR reduction IFN −β versus placebo  
 
 
100
 

An estimated single average efficacy of interferon
beta versus placebo was determined by taking a
3
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weighted average for each interferon beta preparation in their respective trials against placebo.
Simple weighted regression
To assess the relationship between age and ARR,
new T2 lesions, and gadolinium-enhanced lesions
reduction, we fitted a simple weighted regression
to all drug trials as follows using ARR as the
example
ARR Reduction Wi = β 0Wi + β1W Agei + εWi
The parameter estimates of (β) [standard error
(SE) and R2] are reported for each model, the
subscripts Wi are indices of the weighted terms,
and ε is the error term.
Results
There were 26 trials of 14 DMTs enrolling 28,082
subjects published between 1995 and 2019 that
fulfilled inclusion criteria for the meta-analysis.
ARR or a relapse-related metric was the primary or
coprimary outcome in all trials except in the highdose interferon beta-1a trial, which reported time
to onset of sustained disability worsening as the
primary outcome.16 New T2 lesions were reported
as an outcome in 18 trials and gadoliniumenhanced lesions were reported in 19 trials. Each
trial was assigned a weight dependent on the trial
sample size and duration. Eleven active comparator trials compared the study drug with interferon
beta instead of placebo. Six trials compared efficacy of interferon beta with placebo. Individual
trial characteristics are shown in Table 1. For
active comparator trials, the efficacy of the drug
against placebo was estimated by combining the
added estimated ARR, new T2 lesions, or gadolinium-enhanced lesion reduction of interferon beta
against placebo with the ARR, new T2 lesions, or
gadolinium-enhanced lesion reduction of drug to
interferon beta.
Age and ARR
The mean age of patients in all trials ranged from
33.1 years in the CARE-MS I trial17 to 40.4 years
in the FREEDOMS II trial.18 We modeled the
linear regression for 26 trials as a function of age,
and there was no significant association between
mean age and ARR reduction [ β w (SE) = –2.13
(2.1); R2 = 0.04; p = 0.31] [Figure 2(A)].
4

Age and new T2 lesions
The mean age of patients in all trials ranged from
35.4 years in the SUNBEAM trial19 to 40.4 years
in the FREEDOMS II trial.18 We modeled the
linear regression for 18 trials as a function of age,
and there was no significant association between
mean age and new T2 lesion reduction [ β w
(SE) = 1.01 (3.9); R2 = 0.003; p = 0.80] [Figure
2(B)].
Age and gadolinium-enhanced lesions
The mean age of patients in all trials ranged from
35.4 years in the SUNBEAM trial19 to 40.4 years
in the FREEDOMS II trial.18 We modeled the
linear regression for 19 trials as a function of age,
and there was no significant association between
mean age and gadolinium-enhanced lesion reduction [ β w (SE) = –2.25 (3.5); R2 = 0.02; p = 0.53]
[Figure 2(C)].
Discussion
Our meta-analysis found no significant association between age and DMT efficacy on disease
activity as measured by reduction in ARR, new
T2 lesions, or gadolinium-enhanced lesion in
clinical trials of DMTs for RRMS. We chose to
study ARR reduction since approvals of DMTs
are mainly based on this outcome measure. In
addition, MRI lesions are a surrogate of ARR and
are correlated with disease activity.20 In almost all
RRMS trials, ARR or a similar relapse-related
metric was used as the primary outcome, but
studies have not examined whether ARR reduction is age-dependent. Seven subgroup analyses
of MS drug trials studied whether there were differences in efficacy between younger versus older
patients.21–26 In each of these subgroup analyses
patients were separated into two age groups of
above and below age 40 years (with a cutoff of 38
for one study). These results showed that patients
in the younger age group had better treatment of
disease activity, but due to small differences in
treatment effect, these subgroup analyses were
not powered to detect statistical significance of
the effect differences between the two age groups.
A meta-analysis of six randomized controlled trials of 6693 patients with RRMS that reported
subgroup analysis showed that patients in the
<40 age group achieved significantly higher
reduction of disease activity than those in the ⩾40
age group.27 Although subgroup analyses have
shown that DMTs have greater efficacy in
journals.sagepub.com/home/tan

2010

1995

A2

C1

D1

DF1

DF2

F1

F2

F3

G1

G2

G3

G4

I1

I2

I3

CARE-MS II
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CLARITY

DECIDE

CONFIRM

DEFINE

FREEDOMS

FREEDOMS II

TRANSFORMS

The Copolymer
1 MS Study
Group

BEYOND

CONFIRM

CombiRx

MSCRG

PRISMS

PRISMS

1998

1998

1996

2013

2012

2009

2014

2010

2012

2012

2015

2010

2012

2012

A1

CARE-MS I

Year

Index

Trial

Interferon beta-1a
(Rebif)

Interferon beta-1a
(Rebif)

Interferon beta-1a
(Avonex)

Glatiramer
acetate

Glatiramer
acetate

Glatiramer
acetate

Glatiramer
acetate

Fingolimod

Fingolimod

Fingolimod

Dimethyl fumarate

Dimethyl fumarate

Daclizumab HYP

Cladribine

Alemtuzumab

Alemtuzumab

Experimental
arm

Placebo

Placebo

Placebo

Interferon
beta-1a
(Avonex)

Placebo

Interferon
beta-1b
(Betaseron)

Placebo

Interferon
beta-1a
(Avonex)

Placebo

Placebo

Placebo

Placebo

Interferon
beta-1a
(Avonex)

Placebo

Interferon
beta-1a (Rebif)

Interferon
beta-1a (Rebif)

Control arm

277

283

34.90

34.90

36.80

38.31

509

301

36.77

35.60

1345

532

34.45

36.35

251

40.35

866

36.90

38.30

713

843

818

37.50

36.30

1841

540

38.30

35.12

33.07

Mean
age

870

628

563

n

Table 1. Characteristics of clinical trial included in the meta-analysis.

2.00

2.00

1.99

3.00

2.00

2.00

2.00

1.00

2.00

2.00

2.00

2.00

2.76

1.84

2.00

2.00

Trial
duration
(years)

391.74

400.22

424.61

881.61

752.36

1902.12

354.97

866.00

1008.33

1192.18

1156.83

763.68

3058.50

1180.13

888.13

796.20

Weight

32.03

28.91

32.22

28.13

27.50

5.56

29.76

51.52

47.50

55.00

52.78

45.00

43.59

57.58

50.00

53.85

ARR
reduction
% (raw)

32.03

28.91

32.22

50.13

27.50

34.47

29.76

66.36

47.50

55.00

52.78

45.00

60.86

57.58

65.31

67.98

ARR reduction % (recalculated)

—

—

—

—

54.02

–39.39

—

34.62

74.16

74.49

84.71

70.69

54.26

73.43

—

—

New T2
lesion
reduction
% (raw)

—

—

—

—

54.02

33.07

—

68.60

74.16

74.49

84.71

70.69

78.03

73.43

—

—

New T2
lesion
reduction %
(recalculated)

—

—

51.52

—

65.00

–33.33

—

54.90

66.67

81.82

94.44

75.00

60.00

86.81

—

—

Gadoliniumenhanced
lesion
reduction %
(raw)

(Continued)

—

—

51.52

—

65.00

59.64

—

86.35

66.67

81.82

94.44

75.00

87.89

86.81

—

—

Gadoliniumenhanced
lesion reduction % (recalculated)
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5

6

Index

I4

I5

I6

L1

L2

N1

N2

O1

O2

OZ1

OZ2

T1

T2

T3

T4

Trial

INFB MS Study
Group

ADVANCE

BRAVO

ALLEGRO

BRAVO

AFFIRM

SENTINEL

OPERA I

OPERA II

SUNBEAM

RADIANCE

TEMSO

TEMSO

TOWER

TOWER

Table 1. (Continued)

2014

2014

2011

2011

2019

2019

2016

2016

2006

2006

2014

2012

2014

2014

1995

Year

Teriflunomide
(14 mg daily)

Teriflunomide
(7 mg daily)

Teriflunomide
(14 mg daily)

Teriflunomide
(7 mg daily)

Ozanimod

Ozanimod

Ocrelizumab

Ocrelizumab

Natalizumab + interferon beta-1a
(Avonex)

Natalizumab

Laquinimod

Laquinimod

Interferon beta-1a
(Avonex)

Pegylated interferon beta-1a

Interferon beta-1b
(Betaseron)

Experimental
arm

Placebo

Placebo

Placebo

Placebo

Interferon
beta-1a
(Avonex)

Interferon
beta-1a
(Avonex)

Interferon
beta-1a (Rebif)

35.55

874

564

601

541

38.17

37.63

38.00

37.73

35.35

895

548

37.30

37.00

835

821

38.90

1171

Interferon
beta-1a
(Avonex) + placebo
Interferon
beta-1a (Rebif)

36.00

37.10

38.70

38.00

36.60

35.50

Mean
age

942

659

1106

672

1012

247

n

Placebo

Placebo

Placebo

Placebo

Placebo

Placebo

Control arm

1.61

1.52

2.07

2.07

2.00

1.13

1.84

1.84

2.00

2.00

2.00

2.00

2.00

0.92

5.00

Trial
duration
(years)

715.64

740.96

778.36

788.43

1236.02

951.40

1132.65

1113.66

1656.04

1332.19

931.97

1564.12

950.35

970.68

552.31

Weight

36.00

22.00

31.48

31.48

39.29

48.57

44.83

44.83

54.67

68.00

17.65

23.08

23.53

35.00

30.36

ARR
reduction
% (raw)

36.00

22.00

31.48

31.48

57.87

64.32

61.72

61.72

68.55

68.00

17.65

23.08

23.53

35.00

30.36

ARR reduction % (recalculated)

—

—

69.51

47.56

42.14

48.24

82.63

77.31

83.33

82.72

16.50

29.55

36.49

66.97

—

New T2
lesion
reduction
% (raw)

—

—

69.51

47.56

72.22

75.15

91.66

89.10

92.00

82.72

16.50

29.55

36.49

66.97

—

New T2
lesion
reduction %
(recalculated)

—

—

80.45

57.14

51.35

62.79

95.24

93.10

88.89

91.67

21.37

37.26

61.54

85.71

—

Gadoliniumenhanced
lesion
reduction %
(raw)

—

—

80.45

57.14

85.27

88.74

98.56

97.91

96.64

91.67

21.37

37.26

61.54

85.71

—

Gadoliniumenhanced
lesion reduction % (recalculated)
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Figure 2. Efficacy of disease-modifying therapies against placebo on annualized relapse rate reduction (A),
new T2 lesion reduction (B), and gadolinium-enhanced lesion reduction (C) as a function of mean baseline
age in patients with relapsing–remitting multiple sclerosis. The corresponding trial indices are listed in
Table 1. The gray area indicates 95% confidence interval estimates. The coefficient of determination (R2) and
p-values are shown in the respective plots. The diameter of each circle is proportional to the weight of the
corresponding clinical trial in the meta-analysis.
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younger patients, the studies do not describe a
correlation between age and efficacy, thus limiting strategies to predict the average efficacy of
DMTs based on age.
Analysis of data for the study was based on methods described in the meta-analysis by Weideman
et al., which evaluated the age-dependent efficacy
of DMTs in trials of all MS subtypes using disease progression as the outcome.11 The original
study found a significant age-related decline in
inhibition of disease progression using a weighted
regression of percent inhibition of disability progression versus mean trial age. The results support
observations that mechanisms driving disease
progression evolve with age. While the mechanisms driving disease activity do not change with
age, disease activity as the substrate for DMTs
diminishes with age, which is not adequately captured in the clinical trial population that selects
for patients with baseline active disease regardless
of age.
Several limitations are inherent in our meta-analysis. The most significant limitation is the inaccessibility of individual-level data from MS
clinical trials, which restricts us to using the mean
patient age as reported in each trial and masks
any age-related changes in DMT efficacy within
each trial. Another limitation is the narrow range
of mean age of trials for RRMS spanning from 33
to 40 years, leaving out aggregate data for younger
and older patients. In addition, we assume that
class differences between DMTs exhibit similar
age-related changes in efficacy and that different
interferon beta preparations are equivalent when
preparing the regression of drug to placebo for
active comparator trials. Finally, variations among
clinical trials, including trial design and changes
in trial population, limit accurate assessment of
comparative drug efficacies.28
Considering that clinical trials of DMTs for
RRMS exclude patients over age 55, there are
no data to suggest DMTs are either effective or
safe in the elderly, especially in those without
disease activity. Instead, there is growing evidence showing increased prevalence of comorbidities in the aging MS population as well as
greater susceptibility to treatment-related side
effects such as infections and lymphopenia.29–31
In addition, evidence suggests that relapses are
rare in people with MS over age 60,31 and continuing DMTs have lower projected benefits in
8

the elderly.32 Despite growing concerns regarding safety and efficacy in using DMTs in the
elderly, their continued use in this population
may be the result of the perceived notion that
disease inactivity is due to the effect of DMTs
rather than the natural disease course with
aging. Further contributing to the hesitation to
discontinue DMT is the concern of rebound
disease activity. The currently ongoing
DISCOMS trial is expected to provide data on
the safety of DMT discontinuation for stable
MS patients over age 55.33
The age gap between the MS clinical trial population and real-world population continues to
widen with growing numbers of elderly people
with MS, where the average age demographics for
people with MS in North America are now cited
to span the 50s to 60s.34,35 This makes clinical
trial results less applicable to the general MS population in terms of age and age-related changes in
disease activity. As the probability of active disease declines with age and susceptibility to side
effects increases, the risks versus benefits of using
DMTs in the elderly should be reexamined.
Current data from clinical trials of DMTs are not
suitable for establishing an age-dependent relationship with efficacy due to selection for patients
with active disease. Further dedicated studies
with a real-world population on the relationship
between DMT efficacy and age and the safety of
DMT discontinuation are still needed to address
the benefits and risks of using DMTs in aging MS
patients.
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